TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 0:00 · $AMD · "AMD’s Free Cash Flow Is About to Explode"
episode briefing
Antonio Linares

"AMD’s Free Cash Flow Is About to Explode"

2025-11-05 · 4 company · 3 thematic
sentiment
3 bull0 bear1 neu
speakers
antonio linares

Antonio Linares runs a concentrated six-stock portfolio plus micro investments, focusing on 'singularity scalers' — companies with proprietary data moats that compound value via AI scaling laws. He bought Palantir at ~$7, held through 2022-2024 drawdowns, and teaches a course on modern value creation processes. His framework emphasizes betting early on extraordinary companies, holding forever, and learning from concentrated mistakes.

quote
“The graph you see on the screen shows free cash flow per share inflecting upwards. The main driver of that inflection of free cash flow per share going up is AMD's ability to mix and match compute engines... So long as these AI scaling law…”
—antonio linares
now playing · $AMD
$AMD···bullish· high· posantonio linares
AMD free cash flow per share inflecting exponentially on chiplet platform and AI scaling laws
AMD's chiplet architecture enables mixing and matching compute engines (CPU, GPU, FPGA) for total cost of ownership advantage across distributed AI workloads; FCF per share will t…
$NVDA···neutral· mediumantonio linares
Nvidia monolithic large-chip approach less suited for distributed AI vs AMD chiplet agility
Nvidia excels at moving electrons quickly in large monolithic chips for big data centers with relaxed thermodynamic constraints, but AMD's chiplet platform is more nimble for dist…
$PLTR···bullish· high· posantonio linares
Palantir driving customer top-line growth and margin expansion; bought in 2022 when hated
Palantir's software increases customers' revenue and margins directly, creating a productivity boom; purchased when consensus viewed it as a consulting company, similar to Spotify…
$LLY···bullish· lowantonio linares
Eli Lilly not just a GLP-1 company but precision medicine at scale
Market reduces Eli Lilly to GLP-1 obesity drugs, but the real value is precision medicine at scale for everyone, analogous to mispriced Spotify and Palantir.